Genmab, a leading biotechnology company, has launched its "AI Everywhere" initiative, providing ChatGPT Enterprise access to over 2,000 employees, aiming to transform its approach to cancer treatment research and operational efficiency.
Genmab, known for developing next-generation antibody therapies for cancer and other serious diseases, has taken a bold step by integrating artificial intelligence into every aspect of its operations. The company's recent adoption of OpenAI's ChatGPT Enterprise across its workforce marks a significant milestone in its mission to transform patient care through innovative "knock-your-socks-off" (KYSO®) antibody treatments.
Tahi Ahmadi, Executive Vice President and Chief Medical Officer, Head of Experimental Medicines at Genmab, underlined the company's ambition: "Genmab's ambition is to integrate AI into everything we do. We anticipated AI to contribute significantly to the quality of our science, decision making, and efficiency in bringing medicines to patients."
The rapid deployment of ChatGPT Enterprise began just one month after its launch, with initial access granted to 1,000 employees. Now, less than a year later, the "AI Everywhere" initiative has expanded to include nearly the entire company, with more than 2,000 licenses distributed.
To kickstart adoption, Genmab encouraged employees to input their job descriptions into ChatGPT and ask, "What can you do to help me?" This simple yet effective approach has yielded impressive results. A recent survey revealed that employees save an average of 3.5 hours per week using ChatGPT Enterprise, with many reporting that the AI has become indispensable in certain aspects of their work.
Farhat Siddiqui, ChatGPT Product Manager at Genmab, noted the impact on employee learning: "Learning to use ChatGPT has been a transformative journey for our employees. Our comprehensive training programmes and personalised guidance have empowered them to embrace innovative ways of thinking and problem-solving."
The company has developed over 100 custom GPTs to assist with various tasks, from drafting documents and summarising scientific literature to performing advanced data analytics. Recent enhancements to GPT-4's vision capabilities have enabled Genmab to tackle previously impossible tasks, such as interpreting complex documents containing images, text, and numbers in a human-like manner.
One of Genmab's innovative projects leverages GPT-4 to transform the creation of clinical trial documents, including clinical study reports, patient safety narratives, and investigational new drug applications. By integrating the AI model directly with clinical data and feedback, Genmab has taught it to continuously improve its own drafts, mimicking human problem-solving processes.
Another notable development is the AI Translator GPT, which translates complex scientific documents with remarkable accuracy. This tool emulates a human translation team, assuming various roles and employing unique strategies like reverse translation and staging languages to significantly reduce translation time from weeks to hours or minutes.
Hisham Hamadeh, Senior Vice President and Global Head of Data Sciences & AI at Genmab, highlighted the partnership's significance: "Our partnership with OpenAI not only highlights Genmab's commitment to innovation but also aims to unleash every colleague's inner algorithmic leader to truly unlock large language model's potential and discover increasingly novel and progressive ways of leveraging AI to improve, and at times, re-imagine their tasks."
Before implementing ChatGPT Enterprise, Genmab conducted a thorough evaluation of OpenAI's security and privacy compliance measures. This assessment included reviews of data handling practices, encryption standards, and compliance with international regulations like GDPR.